Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-18
2010-06-15
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07737168
ABSTRACT:
Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.
REFERENCES:
patent: 4029666 (1977-06-01), Weber et al.
patent: 4061763 (1977-12-01), Shepard et al.
patent: 4173646 (1979-11-01), Shepard et al.
patent: 6433016 (2002-08-01), Georgiev
patent: 2002/0193443 (2002-12-01), Georgiev
Henderson et al., “Smallpox as a Biological Weapon,” JAMA 281:2127-2137 American Medical Association, (1999).
Downie et al., “The Antibody Response in Man Following Infection with Viruses of the Pox Group,” J. Hyg. 56:479-487 (1958).
Moss, “Poxviridae and Their Replication,” Virology, Chapter 74:2079-2111, (1990) Raven Press, Ltd, NY.
Modlin, “Vaccinia(Smallpox)Vaccine, Recommendations of the Advisory Committee on Immunization Practices(ACIP), 2001” MMWR (Morb Mort Wkly Rep) 50:1-25 (2001).
Engler et al. “Smallpox vaccination: Risk considerations for patients with atopic dermatitis,” J. Allergy Clin Immunol. 110(3):357-365 (2002).
Jackson et al., “Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox,” Journal of Virology, 75(3):1205-1210, American Society for Microbiology (2001).
Bronson et al., “(S)-1-(3-Hydroxy-2-(phosphonylmethoxy)propyl)cytosine(HPMPC): a Potent Antiherpesvirus Agent,” Adv. Exp. Med. Biol. 278:277-283 (1990).
De Clercq et al., “Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines,” Antiviral Research, 8:261-272, Elsevier Science Publishers B.V. (1987).
De Oliveria et al., “Evaluation of Cidofovir(HPMPC, GS-504)against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model,” Antiviral Research 31:165-172, Elsevier Science B.V. (1996).
Snoeck et al., “Phase II Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Cidofovir Topical Gel for the Treatment of Patients with Human Papillomaviurs Infection, ”CID 33:597-602 (2001).
Smee et al., “Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, cowpox, Monkeypox, and Vaccinia Viruses,” Antimicrobial Agents Chemotherapy 46(5):1329-1335 (2002).
Lalezari et al., “Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS,” Ann. Intern. Med. 126(4):257-263 (1997).
De Clercq, “Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections,” Clinical Microbiology Reviews, 14(2):382-397 (2001).
Bauer et al., “Prophylaxis of Smallpox with Methisazone” American Journal of Epidemiology 90(2):130-145 (1969).
De Clercq et al., “Carboxyclic Adenosine Analogues as S-Adenosylhomocysteine Hydrolase Inhibitors and Antiviral Agents: Recent Advances,” Nucleosides Nucleotides 17(1-3):625-634 (1998).
Coulombe et al., “Pharmacokinetics of the antiviral agent 3-deazaneplanocin A,” European Journal of Drug Metabolism Pharmacokinets 20(3):197-202 (1995).
Obara et al., “New Neplanocin Analogues. 7. Synthesis and Antiviral Activity of 2-Halo Derivatives of neplanocin A,” J. Med. Chem. 39:3847-3852 (1996).
Ishitobi et al. “Re-examination of the Cycloaddition of Cycloheptatriene with Maleic Anhydride” Bulletin of the Chemical Society of Japan, vol. 44, 2993-3000 (1971).
Continuation-in-part Co-pending U.S. Appl. No. 11/785,998, filed Apr. 23, 2007, inventor(s) Robert F. Jordan et al.
Continuation-in-part Co-pending U.S. Appl. No. 11/785,997, filed Apr. 23, 2007, inventor(s) Robert F. Jordan et al. which is now allowed.
Bailey Thomas R.
Jordan Robert
Rippin Susan R.
Bianchi Kristin
Kramer Levin Naftalis & Frankel LLP
Saeed Kamal A
Siga Technologies, Inc.
LandOfFree
Compounds, compositions, and methods for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions, and methods for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions, and methods for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164902